XOMA Royalty Enhances Portfolio with Strategic Acquisition of LAVA Therapeutics

San Francisco, Friday, 21 November 2025.
XOMA Royalty Corporation finalizes the acquisition of LAVA Therapeutics, integrating two partnered assets to boost future revenue through milestone and royalty agreements, strengthening its biopharmaceutical position.